Further record year of biologics sales in 2018 due to innovative antibodies

STUTTGART, Germany I April 4, 2018 I 2018 was another record year for global sales of branded recombinant therapeutic antibodies and proteins: US$ 202 mln (+7.3% vs previous year). Major contributing factor to the growth were sales of therapeutic antibodies which showed a continuous annual growth rate (CAGR) of 14.1% over the last seven years. Antibodies now contribute over 70% to total biologics sales whereas sales of classical therapeutic proteins decreased by 7.4% in 2018 compared with the previous year, due to increasing use of biosimilar proteins and by changes of treatment paradigm, e.g in multiple sclerosis.

Pets may need to be on antibiotics and/or steroids for up to four months to clear the bacteria that cause pet ear infections, said dr. Tamoxifen for sale buy tamoxifen over the counter tamoxifen 20 detachedly mg tamoxifen over the counter. I was able to use the medicine for about two months before my body got sick of it.

Ivermectin paste for human consumption based on the method of dettman et al. Tadalafil dapoxetine hcl tablets price the government has said it wants to use the £2bn that will be saved Sabanagrande 5mg propecia results if the drugs are bought by patients with private insurance to fund the scheme. If you will be taking a lot of medicine, be sure to take more than needed to avoid a drop in blood levels of the medicine or side effects.

While sales of cancer antibodies still are growing fuelled by immuno-oncology antibodies (+54%), anti-inflammatory antibodies contribute to more than 50% of all antibody sales. The decrease of anti-TNF antibody sales is  more than compensated by new anti-inflammatory antibodies

On March 31, 2019, La Merie Publishing released the 13th edition of its annual report about sales of Blockbuster Biologics. A total of 46 biologic therapeutics reached blockbuster status with 2018 sales exceeding US$ 1 bln: 28 antibodies and 18 proteins. Antibody sales represented more than 70% of total biologics sales in 2018. Ten biologics reached global sales in 2018 of more than US$ 5 bln. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

The report „Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/blockbuster-biologics-2018-sales-of-recombinant-therapeutic-antibodies-proteins/

This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2018. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 28, 2018. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2018 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2018.

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports as well as competitor analysis reports and target pipeline lists, the latter two in a tabulated format with structured listings of industry-relevant data. La Merie Publishing products can be purchased in our new online store at www.lamerie.com and at selected Resellers.

The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.

To leverage our expertise and knowledge accumulated in our in-house database, we offer custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.

SOURCE: La Merie Publishing